Biochemical Pharmacology Discussion Group
The New York Academy of Sciences
Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.
DONATEPosted May 28, 2020
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease with few treatment options. Research on IPF and other interstitial lung diseases has historically focused on fibroblasts and the importance of TGF-beta-driven epithelial to mesenchymal transition. Recently, new data have highlighted key roles for additional cell types, including alveolar epithelial cells and endothelial cells, in the development or maintenance of lung fibrosis. Moreover, cellular senescence and immune pathways have also been found to contribute to IPF pathogenesis. This eBriefing showcases emerging biological mechanisms underlying the etiology of pulmonary fibrosis and explores novel ways to remove, repair or regenerate damaged lung.